Overview
- INFevo said it completed a Pre‑A financing round of more than ¥100 million, led by new investors including Xinglian Capital and Prosperity7 Ventures with follow‑on investments from Shunwei Capital, Sequoia China and others.
- The company presented a roadmap to pour the money into AI for Science infrastructure, high‑throughput automation and the Recursive Scientific Discovery (RSD) framework to make research outputs reusable.
- INFevo described OCOO‑T, its transcriptome‑based virtual‑cell model, as posting industry‑leading results on the Tahoe100M, Replogle and PBMC single‑cell perturbation benchmarks in same‑condition tests.
- The firm says its platform creates a closed loop where model predictions guide which wet‑lab perturbations to run and experimental data then retrains models to speed target finding, virtual screening and early efficacy assessment.
- All technical claims and the financing details are based on the company’s disclosure and have not been independently verified, but the move highlights a wider industry push to pair AI models with automated labs to ease wet‑lab throughput limits and speed early drug discovery.